Authors

Alicia K. Morgans, MD, MPH, Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Latest:

Advances in Nonmetastatic CRPC

An overview of drug approvals for nonmetastatic castration-resistant prostate cancer (CRPC), and discussion regarding the potential utility of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) to guide treatment decisions.

Thomas E. Merchant, DO, PhD

Latest:

Dr. Merchant on the Importance of Continued Care in Pediatric Craniopharyngioma

Thomas E. Merchant, DO, PhD, discusses the importance of continued care in pediatric patients with craniopharyngioma.

R. Gregory Bociek, MD

Latest:

Dr. Bociek on the Clinical Uncertainty of MRD Negativity in CLL

R. Gregory Bociek, MD, discusses the clinical uncertainty of minimal residual disease negativity in chronic lymphocytic leukemia.

Brian M. Slomovitz, MD, Florida International University

Latest:

Dr. Slomovitz on the Key Objectives of the KEYNOTE-B21 Trial in High-Risk Endometrial Cancer

Brian M. Slomovitz, discusses the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.

Michelle Shiller, MD

Jeremy L. Ramdial, MD

Latest:

Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant

Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.

Neha Mehta-Shah, MD

Latest:

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL

Neha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.

Reena V. Jayani, MD

Latest:

Evidence Supports Value of Physical Activity in Patients With Cancer

Baseline physical activity and physical function prior to a cancer diagnosis or treatment affects survival, with evidence spanning across solid tumor types and hematologic malignancies.

Marina Sharifi, MD, PhD,

Latest:

Dr Sharifi on the Importance of ctDNA Testing in Breast Cancer

Marina Sharifi, MD, PhD, discusses the benefit of utilizing personalized and targeted therapy approaches in the treatment of patients with breast cancer.

Sathya Neelature Sriramareddy, MD, PhD

Latest:

Dr Sriramareddy on the Relationship Between Uveal Melanoma and the Liver Metastases

Sathya Neelature Sriramareddy, MD, PhD, discusses how the interaction between uveal melanoma cells and the liver microenvironment could influence metastasis growth and therapeutic response.

Jason Starr, DO

Latest:

Dr. Starr on the Characterization of POLE/POLD1 Mutations in Colorectal Adenocarcinoma

Jason Starr, DO, discusses the characterization of POLE/POLD1 mutations in colorectal adenocarcinoma.

Sarah Weiss, MD

Latest:

Dr Weiss on the Ongoing Investigation of Tebentafusp With or Without Pembrolizumab in Non-Uveal Melanoma

Sarah Weiss, MD, discusses the ongoing phase 2/3 TEBE-AM trial of tebentafusp with or without pembrolizumab in a subset of pretreated patients with non-uveal melanoma.

Martin Dietrich, MD, PhD, Florida Cancer Specialists & Research Institute

Latest:

Strategic Approaches to Biomarker Testing in NSCLC: Optimal Timing

Experts reflect on the evolving landscape of biomarker testing in lung cancer, examining its crucial role in treatment decisions and advancements in perioperative and adjuvant therapies.

Sunil Adige, MD

Latest:

Dr Adige on Improving QOL Post–Breast Cancer Treatment

Sunil Adige, MD, discusses aspects of post-treatment care that can improve long-term quality of life and reduce the risk of breast cancer recurrence.

Musa Yilmaz, MD

Latest:

Dr Yilmaz on HB-200 Arenavirus Plus Pembrolizumab in HPV16+ Head and Neck Cancer

Emrullah Yilmaz, MD, PhD, discusses HB-200 arenavirus–based immunotherapy plus pembrolizumab in recurrent/metastatic HPV16+ head and neck cancer.

Emily Skotte, MSN

Latest:

Emily Skotte, MSN on Rash Management in Patients Treated With EGFR TKIs

Emily Skotte, MSN, discusses common ways to manage the rashes that may occur as adverse effects in patients treated with EGFR TKIs.

Gabriella Smith, MD

Latest:

Dr Smith on Next Steps With the KELIM Score and HIPEC in Epithelial Ovarian Cancer

Gabriella Smith, MD, discusses the predictive value of KELIM for survival outcomes with HIPEC at the time of surgery in epithelial ovarian cancer.

Siddhartha Yadav, MBBS, MD

Douglas A. Tremblay, MD

Latest:

Dr Tremblay on the Identification and Prevalence of MDS/MPN Overlap Syndromes

Douglas A. Tremblay, MD, discusses the prevalence of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes and the evolving treatment paradigm for these diseases.

Fady Ghali, MD

Latest:

Dr. Ghali on Nectin-4 and TROP-2 Expression in Urothelial, Variant Histology Bladder Cancer

Fady Ghali, MD, discusses the expression of Nectin-4 and TROP-2 in variant histology bladder cancer and urothelial cancer.